Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Kedar S, Vaidya"'
Autor:
Erwin R. Boghaert, Xin Lu, Paul E. Hessler, Thomas P. McGonigal, Anatol Oleksijew, Michael J. Mitten, Kelly Foster-Duke, Jonathan A. Hickson, Vitor E. Santo, Catarina Brito, Tamar Uziel, Kedar S. Vaidya
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 9, Pp 695-706 (2017)
Improving the congruity of preclinical models with cancer as it is manifested in humans is a potential way to mitigate the high attrition rate of new cancer therapies in the clinic. In this regard, three-dimensional (3D) tumor cultures in vitro have
Externí odkaz:
https://doaj.org/article/6657b2f38afc4560b02a1a64b41eee38
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af9a53ea623c6dab8499fd2219a76bc
https://doi.org/10.1158/1535-7163.c.6538540.v1
https://doi.org/10.1158/1535-7163.c.6538540.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Amino Acid Sequence of AM-1 VH Region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4690d3c6ba234726f181827c74d28b66
https://doi.org/10.1158/1535-7163.22505197
https://doi.org/10.1158/1535-7163.22505197
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Table S1: Mouse Strains Used for Xenograft Studies; Table S2: ABT-414 Growth Inhibition of Xenograft Tumors; Figure S1: Efficacy of ABT-414, ABT-806-vcMMAE, and unconjugated MMAE co-dosed with ABT-806 in U87MGde2-7 Tumor-Bearing Mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161f204be3c985a50dfa14ac1e0540f9
https://doi.org/10.1158/1535-7163.22506979
https://doi.org/10.1158/1535-7163.22506979
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::313f2d242d9ae4aea09b4db055c77042
https://doi.org/10.1158/1535-7163.c.6537985.v1
https://doi.org/10.1158/1535-7163.c.6537985.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
In vivo Efficacy of ABBV-321 tumor targeting.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677c6299c1714e54b6ad5827987299cc
https://doi.org/10.1158/1535-7163.22518654
https://doi.org/10.1158/1535-7163.22518654
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d6b8106485307d7fd6d8f1fb1b654d
https://doi.org/10.1158/1535-7163.c.6542049
https://doi.org/10.1158/1535-7163.c.6542049
Autor:
Edward B. Reilly, Louie Naumovski, Joann P. Palma, Edward K. Han, Qian Zhang, Lora Tucker, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Mark G. Anderson, Jieyi Wang
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da2bd78ea69eb0cc09b70d81041cc0c
https://doi.org/10.1158/1078-0432.c.6526458
https://doi.org/10.1158/1078-0432.c.6526458
Autor:
Edward B. Reilly, Louie Naumovski, Joann P. Palma, Edward K. Han, Qian Zhang, Lora Tucker, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Mark G. Anderson, Jieyi Wang
ABBV-399, a c-Met Antibody Drug Conjugate that Targets Both MET Amplified and c-Met Overexpressing Tumors, Irrespective of MET Pathway Dependence. Figure S1 shows ABBV-399 is internalized upon binding to tumor cells. Figure S2 shows the down-regulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d3a01cbd3c45e92267639c0dd014a8
https://doi.org/10.1158/1078-0432.22466868
https://doi.org/10.1158/1078-0432.22466868
Autor:
Danny R. Welch, Tomoo Iwakuma, Animesh Dhar, Aimee Landar, Anne R. Diers, Warren L. Denning, Keke M. Pounds, Scott W. Ballinger, Kyle P. Feeley, Kevin T. Nash, Kedar S. Vaidya, Benjamin H. Beck, Wen Liu
PDF file - 1105K, Supplemental Figure 7. KISS1 inhibits glucose uptake and activation of AMPK. A, Glucose uptake by C8161.9Vector (Vec), C8161.9KFMΔSS, C8161.9KFM and C8161.9KFM/shPGC1α cells was measured using 2-deoxyglucose uptake and normalized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b85d41efd5088c9dc790e8b2258cd4
https://doi.org/10.1158/0008-5472.22400877.v1
https://doi.org/10.1158/0008-5472.22400877.v1